Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-839-4 | CAS number: 75-10-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
- Endpoint:
- specific investigations: other studies
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, guideline study, available as unpublished report, no restrictions, fully adequate for assessment
- Principles of method if other than guideline:
- The anaesthetic potential of HFC-32 was assessed by exposing 4 groups of mice, each for a period of 10 minutes, to atmospheres of the test substance at target concentrations of 7.5, 15, 25 and 50%. The study design was non-standard and no specific test guideline was available.
- GLP compliance:
- yes
- Type of method:
- in vivo
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: CD-1, Charles River Ltd.
- Housing: individually
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.5-22.5
- Humidity (%): 30-66
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- inhalation
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- each single group of mice was exposed continuously for 10 minutes (whole-body exposure)
- Frequency of treatment:
- once
- Post exposure period:
- 1 and 2 hours
- Remarks:
- Doses / Concentrations:
7.5, 15, 25 and 50%
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
7.6, 15, 26, 50.5%
Basis:
analytical conc. - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Examinations:
- - Mortality: twice daily
- Clinical signs: during exposure, 1 and 2 hours after exposure
- Body weight: daily (during acclimation period and day of exposure) - Details on results:
- Mortality:
No mortality was observed.
Clinical signs:
No anaesthesia was seen during exposure of mice up to 50% (v/v) of HFC-32.
Higher grooming/cleaning activity seen at higher concentrations may be consistent with an excitatory phase prior to attaining an anaesthetised state.
Signs consistent with a definite pre-anaesthetic effect were seen during exposure at 15%, evidenced by reduced locomotory activity in one mouse and slight ataxia in all mice towards in the second half end of exposure. These signs got more and more prominent as the concentrations increased.
At up to 50% HFC-32 in air (with added oxygen to maintain 21% O2) effects were seen earlier than previous concentrations and were more pronounced. Signs consistent with CNS compromise (paddling of limbs, general unsteadiness and lack of balance) were evident during exposure, and may be considered consistent with a pre-anaesthetic phase, although no animals became unconscious.
Bodyweight:
There were no treatment-related effects. - Conclusions:
- No anaesthesia resulted from exposure to 7.5, 15, 25 or 50% HFC-32 for 10 minutes. The effects seen lead to the conclusion that the EC50 (10 minutes) is greater than 50%.
- Endpoint:
- specific investigations: other studies
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant study, available as unpublished report, no restrictions, fully adequate for assessment (SIDS score: 1b).
- Principles of method if other than guideline:
- Method accoding to Reinhardt et al.; Arch. Env. 1971; 22: 265-279
- GLP compliance:
- yes
- Type of method:
- in vivo
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS:
- Source: Interfauna UK (Abbots Ripton Road, Wyton, Huntingdon, Cambridgeshire)
- Age: 6-7 months
- Weight at study initiation: 11.4-14.9 kg
- Diet: 400 g/daily
- Water: ad libitum - Route of administration:
- inhalation
- Vehicle:
- other: clean air
- Details on exposure:
- ADMINISTRATION:
- Adrenaline dose: 2, 4 or 8 µg/kg (chosen animal to animal)
- Type of exposure: snout only
- Exposure schedule: On M0 (minute 0) an ECG is launched, with a subsequent adrenaline injection on M2. The exposure to the test substance starts on M7 and still runs during a second adrenaline injection on M12 and afterwards. Exposure and ECG recording are both stopped on M17. Each animal is exposed to every concentrations in a dose-increasing order but two consecutive experiments are not performed on the same day, allowing thus the animal to recover.
- Atmosphere generation: the test substance is a gas and was therefore directly diluted with air and oxygen before being administered to dogs by using a respiratory mask at an air flow of 40 l/min. In contrast, positive control substance was a liquid and required therefore a vaporiser. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentrations monitoring: The test atmosphere was sampled continuously using a metal bellows pump and analysed using a Miran lA CVF infra-red gas analyser. The output of the analyser was recorded continuously on a Philips PM 8252 chan recorder. The measuring wavelength for CFC 11 was 12.1 µm and for HFC 32 was 9.0 µm.
- Duration of treatment / exposure:
- Exposure period: 10 minute(s)
- Frequency of treatment:
- Each animal is exposed once to every concentrations in a dose-increasing order but two consecutive experiments are not performed on the same day, allowing thus the animal to recover.
- Remarks:
- Doses / Concentrations:
15, 20, 25, 30 and 35 % v/v in air
Basis:
nominal conc. - No. of animals per sex per dose:
- 8
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- PRINCIPLE OF THE TEST:
This test aims at detecting potential for cardiac sensitisation to adrenaline of a test substance. Cardiac sensitisation can be defined as the ability of the test substance to induce multiple mutifocal ectopic beats following adrenaline intravenous injection. The study is divided into three stages:
- Stage 1: Prior to the exposure to the test substance, animals are first exposed to increasing intravenous adrenaline doses until ectopic beats are detected by electrocardiogram (ECG). This dose is then selected for being used in the following stages and will not exceed 12 µg/kg.
- Stage 2: Animals are exposed to a positive control substance after an adrenaline injection.
- Stage 3: Animals are exposed to the test substance after an adrenaline injection. - Examinations:
- EXAMINATIONS:
- Clinical signs: yes
- Electrocardiogram: The standard Lead II electrocardiogram was applied throughout the study. Appropriate areas on the dog limbs were shaved and electrode gel applied. Standard ECG limb leads were then connected to the prepared areas on the dog with blunt clips. The electrocardiograph (Devices 3442 ECG amplifier with a two-channel chan recorder) was calibrated with 1 mV peaks and then switched over to Lead II settings.
- Evaluation criteria: The criterion for a positive effect was the appearance of a burst of multifocal ventricular ectopic activity (MVEA) or ventricular fibrillation (VF). Ventricular tachycardia alone is not always definitive evidence of a positive response. - Positive control:
- CFC11 (2%)
- Details on results:
- CLINICAL SIGNS:
Head tremors and limb tensing were observed in most of dogs at 30 and 35% HFC 32 and at 2% CFC 11.
CARDIAC FINDINGS:
In stage 1, once a siutable dose was chosen for a dog, the response to that dose was found to be consistent throughout the study. The results of stage 2 indicate that the experimental model is sensitive to cardiac sensitising agents. The results of stage 3 show that HFC 32 does not induce cardiac sensitisation (no positive responses) at the concentrations tested (15 %, 20 %, 25 %, 30 %, 35 %). Two dogs 409 & 417 each showed a short burst of ectopic activity at 15 % and 35 % HFC 32 respectively. Dog 409 did not show a response at higher concentrations and was therefore considered negative. Dog 417 was not exposed above 35% HFC 32 but data from stage 1 shows that spontaneous ectopic activity is possible without exposure to the test gas. It is therefore concluded that HFC 32 does not induce cardiac sensitisation to adrenaline in the dog at or below concentrations of 35% HFC 32 in air. In contrast, exposure to positive control substance (CFC 11) showed a positive response in 62.5% of dogs. - Conclusions:
- Whatever the tested concentration up to 35% in air, HFC 32 does not induce cardiac sensitisation to adrenaline in the dog.
- Endpoint:
- specific investigations: other studies
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant study, available as unpublished report, no restrictions, fully adequate for assessment (SIDS score: 1b).
- Principles of method if other than guideline:
- Method according to Lazarow's method (1981)
- GLP compliance:
- no
- Type of method:
- in vitro
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS:
- Source: Charles River France (Saint-Aubin-les-Elbeuf, 76410 Cléon, France)
- Cell type: hepatocytes - Route of administration:
- other: in vitro
- Vehicle:
- other: air
- Details on exposure:
- in vitro method
- Details on analytical verification of doses or concentrations:
- not applicable
- Duration of treatment / exposure:
- Exposure period: 4 day(s)
- Frequency of treatment:
- once
- Post exposure period:
- None
- Remarks:
- Doses / Concentrations:
10, 30, 40, 50, 60, 70 80 and 90% v/v in air
Basis:
nominal conc. - No. of animals per sex per dose:
- not applicable (in vitro method)
- Control animals:
- other: untreated and DMF (dimethylformamide)
- Details on study design:
- PRELIMINARY STUDY:
A cytotoxicity study was performed in a dose-finding purpose. The following concentrations were tested: 10, 30, 40, 50, 60, 70, 80 and 90%.
MAIN STUDY:
Hepatocytes harvesting: an anesthetized rat was perfused in its portal vein with 200 ml buffered Hank's saline solution containing EGTA (ethylene glycol-bis(beta-aminoethyl)N-N'-tetracetic acid) followed by 250 ml of Williams medium E (WME) supplemented with 5 mM Ca2+ and containing collagenase. Liver was then removed and the capsule was opened. Cells were collected in WME+collagenase medium and washed once with Leibowitz L15 medium supplemented with 9% calf serum.
- Treatment: After being inoculated in round, flat-bottomed sterile glass bottles (with screw-capped lids), cells were exposed to various atmospheric concentrations of test compounds.
- Vehicle: sterile air
- Incubation temperature: 37°C
- Number of replicates: 3 - Examinations:
- EXAMINATION:
Palmitoyl-CoA-oxidase activity: Cells were incubated at 37°C for 11 minutes with radio-labelled palmitoyl-CoA (20 nCi/ml) and cofactors. Reaction was stopped by the addition of 250 µl of perchloric acid at 18°C. After one hour on crushed ice, the tubes were centrifugated at 4°C and 3000 rpm for 10 minutes. 250 µl of the supernatant were collected and added to 4.75 ml of scintillant liquid (Ready-safe, Beckmann) in counting vials. Counting was performed using a Beckmann LS 1800 scintillation counter. - Protein content: determined using a Hitachi 717 analyzer, by the Pierce BCA (bicinchoninic acid) method, according to Smith (Anal. Biochem. 1985 ; 150 : 76-85) Results were expressed as nanomol oxidized palmitoyl-CoA per minute and per milligram protein (PCO).
STATISTICAL TEST: No data - Positive control:
- clofibric acid (0.5 M in DMF)
- Details on results:
- PRELIMINARY STUDY:
During the preliminary cytotoxicity study performed at 10, 30, 50, 70 and 90%, using two bottles per concentration, the test substance was found cytotoxic at the concentration of 90% (great number of dead cells). The toxic effect was less pronounced at 50 and 70, and no cytotoxic effect was observed at lower concentrations. Consequently, the concentrations selected for the peroxisome proliferation study were 30, 40, 50, 60, 70 and 80%.
MAIN STUDY:
After a 96-hour culture period, no toxic effect was noted whatever the concentration. Evaluation of palmitoyl-CoA-oxidase activity was performed at the five highest concentrations: 40, 50, 60, 70 and 80%. No increase in the palmitoyl-CoA-oxidase activity was observed whatever the concentration of Forane 32 tested (cf. Attached Document). The positive control (clofibric acid) induced an increase in the PCO activity at the concentration of 0.5 mM (induction factor in relation to the DMF solvent control: 5.5), which confirms the sensitivity of the cultures. - Conclusions:
- Forane 32 is not an in vitro peroxisome inducer in rat hepatocytes.
Referenceopen allclose all
Description of key information
HFC 32 did not show any cardiac sensitisation potential dogs exposed for 10 minutes at concentrations from 150,000 to 350,000 ppm v/v (315000 to 735000 mg/m3).
No increase in the palmitoyl-CoA-oxidase activity was observed at concentrations of 40, 50, 60, 70 and 80% difluoromethane (exposure for 4 days) in hepatocytes from a Sprague-Dawley male rat in a peroxisome proliferation assay.
No anaesthetic effects were seen in CD-1 mice exposed to 0-50% HFC-32 for 10 minutes.
Additional information
HFC 32 did not show any cardiac sensitisation potential to adrenaline in the Beagle dog exposed for 10 minutes at concentrations from 150,000 to 350,000 ppm v/v (315000 to 735000 mg/m3). The substance did not induce any multiple multifocal ectopic beats following adrenaline intravenous injection.
A peroxisome proliferation assay was performed in hepatocytes from a Sprague-Dawley male rat. The cells were cultured in vitro and exposed to concentrations of 40, 50, 60, 70 and 80% of difluoromethane for 4 days. No increase in the palmitoyl-CoA-oxidase activity was observed at any tested concentrations.
No anaesthetic effects were seen in CD-1 mice exposed to 0-50% HFC-32 for 10 minutes. Higher grooming/cleaning activity seen at higher concentrations may be consistent with an excitatory phase prior to attaining an anaesthetised state. Signs consistent with a definite pre-anaesthetic effect were seen during exposure at 15%, evidenced by reduced locomotory activity in one mouse and slight ataxia in all mice towards in the second half end of exposure. These signs got more and more prominent as the concentrations increased. At up to 50% HFC-32 in air (with added oxygen to maintain 21% O2) effects were seen earlier than previous concentrations and were more pronounced. Signs consistent with CNS compromise (paddling of limbs, general unsteadiness and lack of balance) were evident during exposure, and may be considered consistent with a pre-anaesthetic phase, although no animals became unconscious.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.